NewcelX (NCEL) vs Psyence Biomedical (PBM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
NewcelX (NCEL) has outperformed Psyence Biomedical (PBM) over the past year, losing 83.3% versus a loss of 97.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NCEL | PBM |
|---|---|---|
| Share price | $3.05 | $4.99 |
| Market cap | $17.59M | — |
| 1-day change | -2.09% | -2.49% |
| YTD return | +63.68% | -82.59% |
| 1-year return | -83.32% | -97.05% |
| 5-year return | -99.68% | — |
| P/E ratio (TTM) | 5.86 | — |
| EPS (TTM) | $0.52 | $-12.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.60 | $150.78 |
| 52-week low | $1.83 | $1.92 |
| Distance from 52-week high | -83.63% | -96.69% |
| Analyst consensus | none | — |
| Avg. price target upside | +655.34% | — |
| Average volume | 10.28K | 94.85K |
| Shares outstanding | 5.78M | — |
| Employees | 9 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NCEL has outperformed PBM by 13.7 percentage points over the past year.
About NewcelX
NCEL stock →NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
About Psyence Biomedical
PBM stock →Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
NCEL vs PBM FAQ
Which stock has performed better over the past year, NCEL or PBM?
NCEL returned -83.32% over the past 12 months, compared with -97.05% for PBM (price return, excluding dividends). Past performance does not predict future results.
Are NewcelX and Psyence Biomedical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.